2024年4月12日发(作者：)

小分子药物 光动力

英文回答：

Small-molecule photosensitizers are a promising class

of compounds that can be used to generate cytotoxic

reactive oxygen species (ROS) upon irradiation with light.

This property makes them attractive candidates for use in

photodynamic therapy (PDT), a non-invasive cancer treatment

modality that involves the use of light to activate

photosensitizers and induce cell death.

Small-molecule photosensitizers typically have high

tumor uptake and retention, and they can be easily modified

to target specific tumor cells. They also have good tissue

penetration, which makes them suitable for use in treating

tumors that are located deep within the body.

One of the advantages of small-molecule

photosensitizers is that they can be easily combined with

other therapeutic agents, such as chemotherapy drugs or

targeted therapies. This can help to improve the efficacy

of PDT and reduce the risk of drug resistance.

Several small-molecule photosensitizers have been

developed and are currently being evaluated in clinical

trials for the treatment of a variety of cancers. These

compounds have shown promising results in early studies,

and they are expected to play an increasingly important

role in the treatment of cancer in the future.

中文回答：

小分子光敏剂是一类很有前途的化合物，在光照下可产生细胞

毒性活性氧（ROS）。这一特性使得它们成为光动力治疗（PDT）的

有吸引力候选物，PDT是一种非侵入性癌症治疗方式，涉及使用光

来激活光敏剂并诱导细胞死亡。

小分子光敏剂通常具有很高的肿瘤摄取和保留率，并且可以很

容易地对其进行修饰以靶向特定的肿瘤细胞。它们还具有良好的组

织渗透性，这使得它们适用于治疗位于身体深处的肿瘤。

小分子光敏剂的优点之一是它们可以很容易地与其他治疗剂结

合，例如化疗药物或靶向治疗。这有助于提高PDT的疗效并降低耐

药性的风险。

已经研发出多种小分子光敏剂，并且目前正在临床试验中评估

用于治疗各种癌症。这些化合物在早期研究中显示出了有希望的结

果，并且有望在未来的癌症治疗中发挥越来越重要的作用。